Home » Authors » Catherine Hollingsworth

Articles by Catherine Hollingsworth

Early Stage Obesity Deal Nets Amylin $1.075B from Takeda

Nov. 3, 2009

By Catherine Hollingsworth

Amylin Pharmaceuticals Inc. got a double dose of good news Monday, signing a $1 billion-plus deal to co-develop obesity compounds with Japanese partner Takeda Pharmaceutical Co. Ltd., and getting FDA approval for expanded use of diabetes drug Byetta as a first-line therapy. (BioWorld Today)

Novartis Passes on Idenix Lead HCV Antiviral Drug

Nov. 2, 2009

By Catherine Hollingsworth

Idenix Pharmaceuticals Inc. is looking to partner its early stage compound for hepatic C virus (HCV), now that Swiss drugmaker Novartis Pharma AG has taken a pass on it. (BioWorld Today)

Virdante Series A Brings in $47M to Boost New Antibody Program

Oct. 30, 2009

By Catherine Hollingsworth

Clinical Data Raises $47.4M for NDA Work, Phase III Trial

Oct. 29, 2009

By Catherine Hollingsworth

$15M: BioMarin Buys Huxley, Picks Up Rare Disease Drug

Oct. 28, 2009

By Catherine Hollingsworth

Theravance, GSK Begin Final Tests of COPD Combo Treatment

Oct. 28, 2009

By Catherine Hollingsworth

Proximagen Adds Pain, Obesity Drugs in Cambridge Biotech Buy

Oct. 28, 2009

By Catherine Hollingsworth

SuperGen, GSK Try Epigenetics: Up to $375M in Option Structure

Oct. 27, 2009

By Catherine Hollingsworth

Proximagen Adds Pain, Obesity Drugs in Cambridge Biotech Buy

Oct. 26, 2009

By Catherine Hollingsworth

Halozyme Likely to Fund Insulin Studies with $5M Roche Payment

Oct. 23, 2009

By Catherine Hollingsworth

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
Alicorn synthesizes new AAK1 inhibitors
BioWorld Science
Researchers from Alicorn Pharmaceutical Co. Ltd. and Jiangsu Alicorn Pharmaceutical Co. Ltd. have disclosed crystalline salts of compounds acting as...
UTRN gene involved in arthrogryposis, study finds
BioWorld Science
Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...
CFTX-2034 successfully shows promise for post-bariatric hypoglycemia in preclinical research
BioWorld Science
Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist...
GLP-1s need technologies for long-term use
BioWorld
For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...